{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:59:45Z","timestamp":1791140385811,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.drudis.2014.03.013","type":"journal-article","created":{"date-parts":[[2014,3,23]],"date-time":"2014-03-23T08:33:06Z","timestamp":1395563586000},"page":"1114-1124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Considering a new paradigm for Alzheimer's disease research"],"prefix":"10.1016","volume":"19","author":[{"given":"Gillian R.","family":"Langley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2014.03.013_bib0005","series-title":"Innovation and Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products","first-page":"8","author":"US Food and Drug Administration","year":"2004"},{"key":"10.1016\/j.drudis.2014.03.013_bib0010","series-title":"Toxicity Testing in the 21st Century: A Vision and a Strategy","year":"2007"},{"key":"10.1016\/j.drudis.2014.03.013_bib0015","doi-asserted-by":"crossref","first-page":"A348","DOI":"10.1289\/ehp.117-a348","article-title":"TOX 21: new dimensions of toxicity testing","volume":"117","author":"Schmidt","year":"2009","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.drudis.2014.03.013_bib0020","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1021\/tx400021f","article-title":"Profiling 976 ToxCast chemicals across 331 enzymatic and receptor signaling assays","volume":"26","author":"Sipes","year":"2013","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.drudis.2014.03.013_bib0025","series-title":"OECD Series on Testing and Assessment No. 168. Part 1: Scientific Evidence. ENV\/JM\/MONO(2012) 10","article-title":"The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins","author":"OECD","year":"2012"},{"key":"10.1016\/j.drudis.2014.03.013_bib0030","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1073\/pnas.1222878110","article-title":"Genomic responses in mouse models poorly mimic human inflammatory diseases","volume":"110","author":"Seok","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2014.03.013_bib0035","first-page":"1611","article-title":"APP transgenic mice and their application to drug discovery","volume":"26","author":"Howlett","year":"2011","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.drudis.2014.03.013_bib0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.theriogenology.2007.09.030","article-title":"Are animal models as good as we think?","volume":"69","author":"Wall","year":"2008","journal-title":"Theriogenology"},{"key":"10.1016\/j.drudis.2014.03.013_bib0045","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/npp.2008.173","article-title":"Removing obstacles in neuroscience drug discovery: the future path for animal models","volume":"34","author":"Markou","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.drudis.2014.03.013_bib0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.yrtph.2012.09.002","article-title":"The ability of animal studies to detect serious post marketing adverse events is limited","volume":"64","author":"van Meer","year":"2012","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.drudis.2014.03.013_bib0055","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1479-5876-2-14","article-title":"Lost in translation: obstacles to translational medicine","volume":"2","author":"Mankoff","year":"2004","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.drudis.2014.03.013_bib0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/491031a","article-title":"There's more to life than rats and flies","volume":"491","author":"Bolker","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.03.013_bib0065","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1476-5381.2011.01299.x","article-title":"Animal models in the drug discovery pipeline for Alzheimer's disease","volume":"164","author":"Van Dam","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2014.03.013_bib0070","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1001\/jama.296.14.1731","article-title":"Translation of research evidence from animals to humans","volume":"296","author":"Hackam","year":"2006","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.drudis.2014.03.013_bib0075","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/alzrt90","article-title":"Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies","volume":"3","author":"Shineman","year":"2011","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.drudis.2014.03.013_bib0080","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/ana.20741","article-title":"1,026 experimental treatments in acute stroke","volume":"59","author":"O\u2019Collins","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.drudis.2014.03.013_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2006.12.015","article-title":"Lost in translation: treatment trials in the SOD1 mouse and in human ALS","volume":"26","author":"Benatar","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.drudis.2014.03.013_bib0090","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1242\/dmm.002451","article-title":"Mouse models of Huntington disease: variations on a theme","volume":"2","author":"Ehrnhoefer","year":"2009","journal-title":"Dis. Model Mech."},{"key":"10.1016\/j.drudis.2014.03.013_bib0095","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.drudis.2011.08.005","article-title":"Harnessing opportunities in non-animal asthma research for a 21st-century science","volume":"16","author":"Buckland","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2014.03.013_bib0100","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1097\/CCM.0b013e3181fa0468","article-title":"Systematic review of reviews including animal studies addressing therapeutic interventions for sepsis","volume":"38","author":"Lamontagne","year":"2010","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.drudis.2014.03.013_bib0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1747-5333-1-17","article-title":"Who's afraid of Homo sapiens?","volume":"1","author":"Preuss","year":"2006","journal-title":"J. Biomed. Discov. Collab."},{"key":"10.1016\/j.drudis.2014.03.013_bib0110","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1039\/c2lc40089h","article-title":"Microengineered physiological biomimicry: organs-on-chips","volume":"12","author":"Huh","year":"2012","journal-title":"Lab. Chip"},{"key":"10.1016\/j.drudis.2014.03.013_bib0115","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.2165\/11595870-000000000-00000","article-title":"Current and emerging drug treatment options for Alzheimer's disease: a systematic review","volume":"71","author":"Herrmann","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2014.03.013_bib0120","doi-asserted-by":"crossref","first-page":"e1000245","DOI":"10.1371\/journal.pmed.1000245","article-title":"Can animal models of disease reliably inform human studies?","volume":"7","author":"van der Worp","year":"2010","journal-title":"PLoS Med."},{"key":"10.1016\/j.drudis.2014.03.013_bib0125","series-title":"Final Report of the Strategic Research Agenda Workshop on Basic Research","author":"European Union Joint Programme on Neurodegenerative Disease Research","year":"2011"},{"key":"10.1016\/j.drudis.2014.03.013_bib0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/msj.20159","article-title":"Transgenic mouse models of Alzheimer's disease","volume":"77","author":"Elder","year":"2010","journal-title":"Mt. Sinai J. Med."},{"key":"10.1016\/j.drudis.2014.03.013_bib0135","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nn.2647","article-title":"Animal models of neuropsychiatric disorders","volume":"13","author":"Nestler","year":"2010","journal-title":"Nat. Neurosci."},{"issue":"Suppl. 2","key":"10.1016\/j.drudis.2014.03.013_bib0140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.parkreldis.2008.04.003","article-title":"Thoughts on limitations of animal models","volume":"14","author":"Hartung","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"issue":"Suppl. 1","key":"10.1016\/j.drudis.2014.03.013_bib0145","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1745-6215-12-S1-A102","article-title":"Making the most of animal data \u2013 improving the prospect of success in pragmatic trials in the neurosciences","volume":"12","author":"Egan","year":"2011","journal-title":"Trials"},{"key":"10.1016\/j.drudis.2014.03.013_bib0150","doi-asserted-by":"crossref","first-page":"e1001482","DOI":"10.1371\/journal.pmed.1001482","article-title":"Progress in using systematic reviews of animal studies to improve translational research","volume":"10","author":"Hooijmans","year":"2013","journal-title":"PLoS Med."},{"key":"10.1016\/j.drudis.2014.03.013_bib0155","first-page":"53","article-title":"Use with caution: developmental systems divergence and potential pitfalls of animal models","volume":"82","author":"Lynch","year":"2009","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.drudis.2014.03.013_bib0160","doi-asserted-by":"crossref","first-page":"12698","DOI":"10.1073\/pnas.0914257107","article-title":"Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways","volume":"107","author":"Miller","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2014.03.013_bib0165","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1460-9568.2011.07804.x","article-title":"Comparing adult hippocampal neurogenesis in mammalian species and orders: influence of chronological age and life history stage","volume":"34","author":"Amrein","year":"2011","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.drudis.2014.03.013_bib0170","doi-asserted-by":"crossref","first-page":"19049","DOI":"10.1073\/pnas.1003732107","article-title":"Divergent and nonuniform gene expression patterns in mouse brain","volume":"107","author":"Morris","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2014.03.013_bib0175","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3858\/emm.2010.42.5.040","article-title":"Induction of the unfolded protein response and cell death pathway in Alzheimer's disease, but not in aged Tg2576 mice","volume":"42","author":"Lee","year":"2010","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.drudis.2014.03.013_bib0180","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/j.1742-4658.2010.07564.x","article-title":"Animal models of amyloid-\u03b2-related pathologies in Alzheimer's disease","volume":"277","author":"Philipson","year":"2010","journal-title":"FEBS J."},{"key":"10.1016\/j.drudis.2014.03.013_bib0185","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.lfs.2010.04.014","article-title":"Strain specific differences in memory and neuropathology in a mouse model of Alzheimer's disease","volume":"86","author":"Glazner","year":"2010","journal-title":"Life Sci."},{"key":"10.1016\/j.drudis.2014.03.013_bib0190","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.bbr.2004.01.001","article-title":"Differences in spatial learning comparing transgenic p75 knockout, New Zealand Black, C57BL\/6, and Swiss Webster mice","volume":"153","author":"Wright","year":"2004","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.drudis.2014.03.013_bib0195","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1126\/science.277.5327.839","article-title":"Measuring memory in a mouse model of Alzheimer's disease","volume":"277","author":"Routtenberg","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.drudis.2014.03.013_bib0200","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1601-183X.2005.00124.x","article-title":"Behavioral phenotypes of amyloid-based genetically modified mouse models of Alzheimer's disease","volume":"4","author":"Kobayashi","year":"2005","journal-title":"Genes Brain. Behav."},{"key":"10.1016\/j.drudis.2014.03.013_bib0205","doi-asserted-by":"crossref","first-page":"12208","DOI":"10.1523\/JNEUROSCI.0291-13.2013","article-title":"Olfactory functions scale with circuit restoration in a rapidly reversible Alzheimer's disease model","volume":"33","author":"Cheng","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2014.03.013_bib0210","doi-asserted-by":"crossref","first-page":"275","DOI":"10.14573\/altex.2013.3.275","article-title":"Look back in anger \u2013 what clinical studies tell us about preclinical work","volume":"30","author":"Hartung","year":"2013","journal-title":"ALTEX"},{"key":"10.1016\/j.drudis.2014.03.013_bib0215","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/nature10821","article-title":"Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells","volume":"482","author":"Israel","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.03.013_bib0220","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.stem.2013.01.009","article-title":"Modeling Alzheimer's disease with iPSCs reveals stress phenotypes associated with intracellular A\u03b2 and differential drug responsiveness","volume":"12","author":"Kondo","year":"2013","journal-title":"Cell Stem Cell."},{"key":"10.1016\/j.drudis.2014.03.013_bib0225","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00702-012-0839-2","article-title":"Induced pluripotent stem cells as tools for disease modelling and drug discovery in Alzheimer's disease","volume":"120","author":"Ooi","year":"2013","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.drudis.2014.03.013_bib0230","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1016\/j.neuropharm.2011.02.021","article-title":"Induced pluripotent stem cells: a new tool to confront the challenge of neuropsychiatric disorders","volume":"60","author":"Vaccarino","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2014.03.013_bib0235","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fncel.2013.00029","article-title":"Patient-derived stem cells: pathways to drug discovery for brain diseases","volume":"7","author":"Mackay-Sim","year":"2013","journal-title":"Front. Cell Neurosci."},{"key":"10.1016\/j.drudis.2014.03.013_bib0240","doi-asserted-by":"crossref","first-page":"90cm17","DOI":"10.1126\/scitranslmed.3002747","article-title":"Reengineering translational science: the time is right","volume":"3","author":"Collins","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.drudis.2014.03.013_bib0245","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/nrd3577","article-title":"Induced pluripotent stem cells \u2013 opportunities for disease modelling and drug discovery","volume":"10","author":"Grskovic","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.drudis.2014.03.013_bib0250","first-page":"369","article-title":"Induced pluripotent stem cells as human disease models","volume":"vol. 46","author":"Dimos","year":"2011"},{"key":"10.1016\/j.drudis.2014.03.013_bib0255","article-title":"The potential of tissue engineering for developing alternatives to animal experiments: a systematic review","author":"de Vries","year":"2013","journal-title":"J. Tissue Eng. Regen. Med."},{"key":"10.1016\/j.drudis.2014.03.013_bib0260","doi-asserted-by":"crossref","DOI":"10.1186\/scrt361","article-title":"The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline","author":"Sutherland","year":"2013","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.drudis.2014.03.013_bib0265","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-1-60327-258-2_10","article-title":"Automated patch clamping using the QPatch","volume":"565","author":"Jones","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.drudis.2014.03.013_bib0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biosystems.2006.03.012","article-title":"Learning in human neural networks on microelectrode arrays","volume":"88","author":"Pizzi","year":"2007","journal-title":"BioSystems"},{"key":"10.1016\/j.drudis.2014.03.013_bib0275","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1523\/JNEUROSCI.2718-12.2013","article-title":"Short-term memory in networks of dissociated cortical neurons","volume":"33","author":"Dranias","year":"2013","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2014.03.013_bib0280","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nn.3041","article-title":"Human cerebral cortex development from pluripotent stem cells to functional excitatory synapses","volume":"15","author":"Shi","year":"2012","journal-title":"Nat. Neurosci"},{"key":"10.1016\/j.drudis.2014.03.013_bib0285","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nature12415","article-title":"Integrative genomics identifies APOE\u025b4 effectors in Alzheimer's disease","volume":"500","author":"Rhinn","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.03.013_bib0290","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.neurobiolaging.2010.08.017","article-title":"Epigenetic mechanisms in Alzheimer's disease","volume":"32","author":"Mastroeni","year":"2011","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.drudis.2014.03.013_bib0295","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1750-1326-8-20","article-title":"Fluid biomarkers in Alzheimer's disease \u2013 current concepts","volume":"8","author":"Ros\u00e9n","year":"2013","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.drudis.2014.03.013_bib0300","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/pr3001546","article-title":"Label-free quantitative LC-MS proteomics of Alzheimer's disease and normally aged human brains","volume":"11","author":"Andreev","year":"2012","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.drudis.2014.03.013_bib0305","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1471-4159.2012.07737.x","article-title":"Phosphoproteome profiling of substantia nigra and cortex regions of Alzheimer's disease patients","volume":"121","author":"Zahid","year":"2012","journal-title":"J. Neurochem."},{"issue":"Suppl. 3","key":"10.1016\/j.drudis.2014.03.013_bib0310","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3233\/JAD-2011-0023","article-title":"Ultra-high field 7T MRI: a new tool for studying Alzheimer's disease","volume":"26","author":"Kerchner","year":"2011","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.drudis.2014.03.013_bib0315","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.neuron.2013.07.037","article-title":"Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls","volume":"79","author":"Maruyama","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.drudis.2014.03.013_bib0320","first-page":"542","article-title":"Discovery of genes that affect human brain connectivity: a genome-wide analysis of the connectome","volume":"2012","author":"Jahanshad","year":"2012","journal-title":"Proc. IEEE Int. Symp. Biomed. Imaging"},{"key":"10.1016\/j.drudis.2014.03.013_bib0325","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1365-2990.2011.01181.x","article-title":"The three new pathways leading to Alzheimer's disease","volume":"37","author":"Morgan","year":"2011","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.drudis.2014.03.013_bib0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018660","article-title":"Shared molecular and functional frameworks among five complex human disorders: a comparative study on interactomes linked to susceptibility genes","author":"Menon","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2014.03.013_bib0335","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/c92e16da-7733-421d-b063-1db19488daa6","article-title":"Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families","author":"Cruchaga","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.drudis.2014.03.013_bib0340","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer's disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.03.013_bib0345","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/jech-2011-200726","article-title":"Discovering environmental causes of disease","volume":"66","author":"Rappaport","year":"2012","journal-title":"J. Epidemiol. Community Health"},{"key":"10.1016\/j.drudis.2014.03.013_bib0350","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.drudis.2013.01.008","article-title":"Shifting from the single to the multitarget paradigm in drug discovery","volume":"18","author":"Medina-Franco","year":"2013","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2014.03.013_bib0355","series-title":"An NIH White Paper by the QSP Workshop Group","article-title":"Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms","author":"Sorger","year":"2011"},{"key":"10.1016\/j.drudis.2014.03.013_bib0360","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10439-010-0208-y","article-title":"Systems analysis of small signaling modules relevant to eight human diseases","volume":"39","author":"Benedict","year":"2011","journal-title":"Ann. Biomed. Eng."},{"key":"10.1016\/j.drudis.2014.03.013_bib0365","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/clpt.2013.37","article-title":"A map of Alzheimer's disease-signaling pathways: a hope for drug target discovery","volume":"93","author":"Ogishima","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2014.03.013_bib0370","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s11682-012-9196-x","article-title":"Genome-wide pathway analysis of memory impairment in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort implicates gene candidates, canonical pathways, and networks","volume":"6","author":"Ramanan","year":"2012","journal-title":"Brain Imaging Behav."},{"key":"10.1016\/j.drudis.2014.03.013_bib0375","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nature11405","article-title":"An anatomically comprehensive atlas of the adult human brain transcriptome","volume":"489","author":"Hawrylycz","year":"2012","journal-title":"Nature"},{"issue":"Suppl. 7","key":"10.1016\/j.drudis.2014.03.013_bib0380","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2105-13-S7-S10","article-title":"Modeling the interactions of Alzheimer-related genes from the whole brain microarray data and diffusion tensor images of human brain","volume":"13","author":"Park","year":"2012","journal-title":"BMC Bioinform."},{"key":"10.1016\/j.drudis.2014.03.013_bib0385","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.euroneuro.2012.11.010","article-title":"Structural networks in Alzheimer's disease","volume":"23","author":"Reid","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.drudis.2014.03.013_bib0390","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.03.013_bib0395","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled Phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2014.03.013_bib0400","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","article-title":"Targeting soluble Abeta peptide with tramiprosate for the treatment of brain amyloidosis","volume":"28","author":"Gervais","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.drudis.2014.03.013_bib0405","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer's disease \u2013 a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch. Med. Sci."},{"key":"10.1016\/j.drudis.2014.03.013_bib0410","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1471-2202-8-54","article-title":"Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice","volume":"8","author":"Kukar","year":"2007","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.drudis.2014.03.013_bib0415","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"J. Am. Med. Assoc."},{"issue":"Suppl. 2","key":"10.1016\/j.drudis.2014.03.013_bib0420","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0197-4580(04)80800-5","article-title":"Reduced b-amyloid burden, increased C-99 concentrations and evaluation of neuropathology in the brains of PDAPP mice given LY450139 dihydrate daily by gavage for 5 months","volume":"25","author":"Ness","year":"2004","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.drudis.2014.03.013_bib0425","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A Phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"36","author":"Doody","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2014.03.013_bib0430","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo","volume":"35","author":"Seren\u00f3","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.drudis.2014.03.013_bib0435","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.expneurol.2006.01.018","article-title":"Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice","volume":"199","author":"Pedersen","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.drudis.2014.03.013_bib0440","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","article-title":"Rosiglitazone in Alzheimer's Disease Study Group. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease","volume":"6","author":"Risner","year":"2006","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.drudis.2014.03.013_bib0445","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled Phase III study","volume":"30","author":"Gold","year":"2010","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.drudis.2014.03.013_bib0450","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12031-002-0026-2","article-title":"Statin therapy for Alzheimer's disease","volume":"19","author":"Petanceska","year":"2002","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.drudis.2014.03.013_bib0455","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1212\/WNL.0b013e3181d6476a","article-title":"Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe","volume":"74","author":"Feldman","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2014.03.013_bib0460","doi-asserted-by":"crossref","first-page":"6787","DOI":"10.1523\/JNEUROSCI.2377-07.2008","article-title":"Immunotherapy reduces vascular amyloid-beta in PDAPP mice","volume":"28","author":"Schroeter","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.drudis.2014.03.013_bib0465","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A Phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.drudis.2014.03.013_bib0470","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","article-title":"Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease","volume":"69","author":"Blennow","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.drudis.2014.03.013_bib0475","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/489013a","article-title":"Alzheimer's drugs take a new tack","volume":"489","author":"Callaway","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2014.03.013_bib0480","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1586\/eci.11.93","article-title":"Solanezumab for the treatment of mild-to-moderate Alzheimer's disease","volume":"8","author":"Imbimbo","year":"2012","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.drudis.2014.03.013_bib0485","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","article-title":"Safety and biomarker effects of solanezumab in patients with Alzheimer's disease","volume":"8","author":"Farlow","year":"2012","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.drudis.2014.03.013_bib0490","doi-asserted-by":"crossref","first-page":"S138","DOI":"10.1016\/j.jagp.2012.12.182","article-title":"Efficacy and safety of intravenous solanezumab in patients with mild to moderate Alzheimer's disease: results of two Phase 3 studies","volume":"21","author":"Hake","year":"2013","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.drudis.2014.03.013_bib0495","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/mp.2012.106","article-title":"Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model","volume":"18","author":"Steele","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.drudis.2014.03.013_bib0500","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2014.03.013_bib0505","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF03256900","article-title":"Phase III CONCERT trial of latrepirdine","volume":"26","author":"Sweetlove","year":"2012","journal-title":"Pharm. Med."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644614000907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644614000907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:18:03Z","timestamp":1761221883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644614000907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":101,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1359644614000907"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2014.03.013","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considering a new paradigm for Alzheimer's disease research","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2014.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}